Find out what the 60 Minutes Australia news team saw and heard when they visited the INR to investigate the patented INR Alzheimer’s treatment program. The patient and her granddaughter describe in detail her rapid and sustained favorable response. Filmed at the INR in 2010.
Individual results may vary. Some patients do not respond. For further scientific information, please see:
- TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. Edward Tobinick MD, H Gross MD, Alan Weinberger MD, Hart Cohen MD. MedGenMed. 2006 Apr 26;8(2):25.
- Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. Edward Tobinick MD, H Gross MD. Journal of Neuroinflammation. 2008 Jan 9;5:2.
- Perispinal etanercept: a new therapeutic paradigm in neurology. Edward Tobinick MD. Expert Review of Neurotherapeutics. 2010 Jun;10(6):985-1002.
Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label. Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.